Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized

Jennifer J Arnold, Kevin J Blinder, Neil M Bressler

    American Journal of Ophthalmology
    |April 3, 2004
    PubMed
    Summary

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Explicit Inclusion of Diabetes Mellitus Without Retinopathy Within Diabetic Retinopathy Prediction.

    Translational vision science & technology·2026
    Same author

    Multi-OCT-SelfNet: integrating self-supervised learning with multi-source data fusion for enhanced multi-class retinal disease classification.

    Frontiers in systems biology·2026
    Same author

    Retinal imaging and artificial intelligence analysis.

    Handbook of clinical neurology·2026
    Same author

    A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.

    Ophthalmic research·2026
    Same author

    Expert consensus on fundus fluorescein angiography reporting in ophthalmology: a Delphi study.

    The British journal of ophthalmology·2026
    Same author

    Reduction in Pigment Epithelial Detachment Thickness with Faricimab versus Aflibercept 2 mg during Head-to-Head Dosing in TENAYA/LUCERNE.

    Ophthalmology science·2026
    Same journal

    Performance of the ISOLD Score (Interleukin Score for IntraOcular Lymphoma Diagnosis) in the Diagnosis of Vitreoretinal Lymphoma in Clinical Practice.

    American journal of ophthalmology·2026
    Same journal

    Reply to Comment on Visual Field Progression in Glaucoma Patients with Delayed Follow-Up.

    American journal of ophthalmology·2026
    Same journal

    Comment on: "Safety and efficiency reducing retinopathy of prematurity guideline sensitivity: an external validation using a large US-based dataset".

    American journal of ophthalmology·2026
    Same journal

    Reply to Comment on "Clinicopathological and Imaging Distinction Between Ocular Adnexal MALT Lymphoma and IgG4-Related Ophthalmic Disease".

    American journal of ophthalmology·2026
    Same journal

    Comment on: Visual Field Progression in Glaucoma Patients With Delayed Follow-Up.

    American journal of ophthalmology·2026
    Same journal

    Corneal sensitivity changes and nerve plexus abnormalities in noninfectious anterior uveitis.

    American journal of ophthalmology·2026
    See all related articles
    This summary is machine-generated.

    Acute severe visual acuity decrease after photodynamic therapy (PDT) with verteporfin is uncommon. While most patients recover some vision, long-term decreases can occur, necessitating patient warnings about this risk.

    Area of Science:

    • Ophthalmology
    • Retinal Diseases
    • Medical Interventions

    Background:

    • Age-related macular degeneration (AMD) is a leading cause of vision loss.
    • Photodynamic therapy (PDT) with verteporfin is a treatment for certain types of AMD.
    • Understanding adverse events is crucial for patient safety and treatment decisions.

    Purpose of the Study:

    • To detail occurrences of acute severe visual acuity decrease following PDT with verteporfin.
    • To analyze these events within the context of the TAP Investigation and VIP Trial.

    Main Methods:

    • Observational case series design.
    • Retrospective review of identified cases of acute severe visual acuity decrease.
    • Analysis of patient data and associated morphological findings.

    Related Experiment Videos

    Main Results:

    • 14 patients experienced 15 events; one was excluded on review.
    • 11 events occurred after the first PDT treatment.
    • Most patients showed initial visual acuity improvement, but long-term decreases were observed in some.
    • Associated findings included macular detachment, hemorrhage, and hypofluorescence.
    • Events were more likely in patients with better baseline visual acuity (20/50 or better).

    Conclusions:

    • Acute severe visual acuity decrease is an uncommon adverse event after verteporfin PDT.
    • The risk of this event does not outweigh the established benefits of PDT for AMD.
    • Patients should be informed about the potential for this serious adverse event prior to treatment.